Australian Man Lived 105 Days on a Titanium BiVACOR Heart That Was Still Only a Bridge to Someone Else’s Organ
Il n'a pas de nom public. Il est décrit comme australien, dans sa quarantaine, et, pendant 105 jours, comme une personne dont le cœur était un disque de titane tournant dans un champ magnétique. Des chirurgiens de l'hôpital St Vincent's Sydney ont implanté un cœur artificiel total de BiVACOR le 22 novembre 2024. Il a quitté le service. Il a fait ses courses. Il vivait dans des pièces ordinaires avec un câble à travers sa poitrine et un contrôleur de la taille d'un grand manuel, environ cinq livres et demi, attaché par quatre ou cinq pieds de ligne d'entraînement. Début mars 2025, un coeur de donneur est arrivé. La pompe est sortie. C'était la première personne sur Terre sortie d'un hôpital vivant avec cet appareil, et il était toujours un patient de pont, pas un patient permanent.
L'AEGIS Alliance est restée sur l'affaire parce que le langage marketing continue d'essayer de sauter cette distinction. Daniel Timms, l'ingénieur du Queensland qui a commencé la conception en tant que projet de doctorat et qui est maintenant directeur technique, a déclaré à la presse technique que la distribution commerciale pourrait commencer en 2028 si les essais se terminent. Une version entièrement implantable, sans manuel suspendu au corps, est le projet plus long qu'il appelle la thérapie de destination. Les 105 jours ont prouvé qu'un homme pouvait rentrer chez lui. Ils n'ont pas prouvé que la liste d'attente était terminée.
One moving part, and why that mattered
Plus tôt, les cœurs artificiels totaux ont échoué de manière prévisible. Les chambres en plastique fléchissaient jusqu'à fatiguer. Valves cassées. Les machines étaient trop grandes pour beaucoup de poitrines, surtout pour les femmes. BiVACOR est une pompe rotative, de la taille d'un poing et d'environ 650 grammes, usiné à partir de titane. Une roue lévitée magnétiquement, un disque double face qui ne touche jamais un palier, pousse le sang dans un courant continu. Il n'y a pas de rythme cardiaque. Il n'y a pas non plus de surface mécanique qui attend d'être usée à une heure prévue. De grandes lacunes dans la voie sanguine sont destinées à diminuer les chances de caillot.
Dr. Paul Jansz performed the six-hour operation and called the team enormously proud to be first in Australia. The hospital sits on a particular piece of history. Australia’s first heart transplant was done at St Vincent’s in 1968, and the country’s first successful one, by Dr. Victor Chang, in 1984. Cardiologist Professor Chris Hayward has described the 2024 implant as an unmitigated clinical success. Professor Peter MacDonald called it a complete game changer for the queue. Timms stayed close after discharge. In an ABC interview he described an ordinary Uber ride and a patient well enough to joke about getting a pint after the human transplant. « He was a lovely fellow, » Timms said, « very, very grateful. »
Houston went first. Sydney went home.
The Australian man was the sixth human implanted, not the first. On July 9, 2024, surgeons at Baylor St. Luke’s Medical Center in Houston, inside the Texas Heart Institute program that has chased mechanical hearts for generations, put the device into a 58-year-old man under an FDA Early Feasibility Study. Five U.S. patients, all in severe biventricular failure and facing imminent death, were successfully bridged to donor hearts. Because of the way that first study was written, they stayed in intensive care and were relisted quickly. Support times were short. The agency then allowed 15 more patients. In May 2025 the FDA gave the pump Breakthrough Device designation as a bridge to transplant. That is a faster review track. It is not a supermarket approval.
An extended U.S. feasibility study meant to let patients go home began in October 2025. IEEE Pulse reported in June 2026 that one of those patients had carried the heart for three months and spent one of those months outside the hospital, with 14 more people being enrolled. In Australia, regulators had allowed a five-patient series. Four had been done by the middle of 2026, and the unnamed man in his forties still held the duration record at about 104 to 105 days. Timms has said some recipients recovered so fast that transplant teams were ready in days, not months. Speed is a gift to a waiting list. It is also a reminder that the current generation is designed to be explanted.
The bleeds the press conference did not lead with
Two later Australian patients died of bleeding in the brain several weeks after surgery. An independent review, described in the surgical literature in 2026, concluded the hemorrhages were not caused by a defect in the pump. Investigators pointed at blood-pressure control and anticoagulation, the same tightrope every mechanical-support team walks. The families still buried people who had been offered a way station to a second chance. The AEGIS Alliance will not sand that off a titanium success story. A magnetically levitated impeller can be elegant and still sit inside a body that clots or bleeds. Stroke and hemorrhage have haunted total artificial hearts for decades, including the ones with parts that wore out.
Readers of our health coverage have seen the same split elsewhere. A Long Island man freed from sickle cell pain by gene therapy still faces lifelong cancer surveillance and a chemotherapy step that can cost fertility. A single spectacular recovery is not a safety table. BiVACOR is headquartered in Huntington Beach, California, with clinical offices in Houston and an Australian base on the Gold Coast. Australian government money, including support routed through Monash University’s artificial-heart program and the Medical Research Future Fund, helped get the trial onto a Sydney operating table. Public capital does not erase a complication.
Why the donor list still decides
A left-ventricular assist device can hold up one failing side of the heart. Patients whose right and left sides are both finished, or who cannot take an assist device, have had almost nothing except the hope that a donor appears before they die. Before mechanical support became common, about a quarter of the people waiting for a heart died on the list. A durable, smaller total artificial heart is the tool that gap has been missing. If the expanded U.S. study repeats the first five bridges without a wave of device failures, regulators will be pushed to let more centers use it as a planned stepping stone.
The controller is the honest detail. A five-and-a-half-pound box and a driveline through the skin are not a heart you forget. Infection at that cable, power failure, and the daily logistics of batteries are the life the shopping trips did not show on camera. Timms has been clear that a permanent implant, one a person might live with for years without a donor, is a later generation. Company materials still describe this one as a bridge. The American College of Surgeons, writing in 2026, called the moment real momentum and also a defining chapter, which is a careful way of saying the engineering works and the protocol is not finished.
What 105 days were actually for
They showed a surgical team in Sydney could implant the pump, send a person into the city with it, explant it, and complete a human transplant. They showed U.S. regulators were willing to widen a feasibility study and stamp it as a breakthrough device. They did not show that anticoagulation can be standardized, that every later implant will avoid a brain bleed, or that a commercial titanium heart will be sitting on a shelf in 2028. Timms expects the trials to be done and distribution to start that year. Expectation is a schedule, not a warranty.
For one unnamed man, the proof was narrower and more human. He walked out of St Vincent’s. He waited. He received someone else’s heart. The disc that spun in his chest did not get a name on a building. It got him to the next operation. That is a smaller miracle than the headlines sold, and it is still the difference between a funeral in November 2024 and a transplant in March 2025. More of this reporting sits with our science desk et Nouvelles internationales.
